Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · Real-Time Price · USD
15.94
-1.51 (-8.63%)
Mar 31, 2025, 10:44 AM EDT - Market open

Company Description

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States.

Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates.

The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications.

Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases.

Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Korro Bio, Inc.
Korro Bio logo
Country United States
Founded 2014
IPO Date Oct 3, 2019
Industry Biotechnology
Sector Healthcare
Employees 104
CEO Ram Aiyar

Contact Details

Address:
One Kendall Square, Building 600-700
Cambridge, Massachusetts 02139
United States
Phone 617 468 1999
Website korrobio.com

Stock Details

Ticker Symbol KRRO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $14.00
CIK Code 0001703647
CUSIP Number 500946108
ISIN Number US5009461089
Employer ID 47-2324450
SIC Code 2834

Key Executives

Name Position
Dr. Ram Aiyar MBA, Ph.D. Chief Executive Officer, President, Interim Principal Financial Officer and Director
Nessan Bermingham Ph.D. Co-Founder and Independent Chairman of the Board
Vineet Agarwal M.B.A. Chief Financial Officer (Leave of Absence)
Dr. Jean-Francois Formela M.D., MBA Co-Founder and Independent Director
Andrew Fraley Ph.D. Co-Founder and Advisor
Dr. Joshua Rosenthal Ph.D. Co-Founder and Advisor
Todd Chappell M.B.A. Chief Operating Officer
Oliver Dolan Interim Principal Accounting Officer
Jeffrey M. Cerio J.D., Pharm.D. Senior Vice President and General Counsel
Stephanie Engels Senior Vice President and Head of People and Culture

Latest SEC Filings

Date Type Title
Mar 27, 2025 8-K Current Report
Mar 18, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 18, 2025 10-K Annual Report
Mar 18, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G Filing
Feb 11, 2025 8-K Current Report
Feb 5, 2025 SCHEDULE 13G Filing
Jan 13, 2025 8-K Current Report
Dec 10, 2024 424B3 Prospectus